INAB Stock — IN8bio Inc.: Cash, EV, Pipeline

What they do

We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers ("TCEs") for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.93

Market cap

$9.1M

Cash

$14.2M

Enterprise value

-$5.1M

Balance sheet

Cash	$14.2M
Debt	$0.0M
Net cash	$14.2M
Enterprise value	-$5.1M
Basic shares	10.8M shares
Fully diluted shares	21.8M shares
Fully diluted market cap	$20.3M
Cash per share	$1.31
Quarterly burn	$3.7M
Cash runway	4.8 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

9.9M

Pre-funded warrants

9.6M

Options

1.3M

RSUs

0.0M

Warrants

1.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

21.8M

Cap table as of 2026-06-30.

Price history

Loading INAB daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

INB-100

Phase 1 · Active Modality: cell therapy (allogeneic donor-derived expanded and activated gamma-delta T cells, DeltEx)

Indications

Acute myeloid leukemia / high-risk leukemias undergoing haploidentical HSCT (Phase 1)

Catalysts

— late 2026

Status note Lead program. Investigator-sponsored Phase 1 completed primary enrollment; RP2D determined; expansion cohort at RP2D enrolling (target up to 15 additional patients, minimum 25 total).

INB-200

Phase 1 · Active Modality: cell therapy (drug-resistant immunotherapy, DeltEx DRI gamma-delta T cells engineered with MGMT-expressing lentivector)

Indications

Newly diagnosed glioblastoma (GBM) (Phase 1)

Status note Investigator-sponsored Phase 1 (NCT04165941) dosing completed; patients followed for PFS/OS. Peer-reviewed Phase 1 data published in JCO July 2026.

INB-400

Phase 2 · Active Modality: cell therapy (drug-resistant immunotherapy, DeltEx DRI gamma-delta T cells)

Indications

Newly diagnosed glioblastoma (GBM) (Phase 2)

Catalysts

— late 2026

Status note Phase 2 enrollment suspended September 2024 following pipeline review to conserve capital; treatment of enrolled patients completed, IND remains open (10-K). DeltEx DRI gamma-delta T cells in newly diagnosed GBM.

INB-619

Preclinical · Active Modality: T cell engager (gamma-delta TCE, INB-600 platform)

Target CD19

Indications

B-cell-driven autoimmune diseases (e.g. systemic lupus erythematosus) (Preclinical)

Catalysts

— 2H 2026

Status note Proprietary internally developed INB-600 TCE platform candidate; deep B-cell depletion via selective gamma-delta T cell activation/expansion shown (ACR Convergence 2025).

INB-300

Preclinical · Active Modality: cell therapy (targeted non-signaling gamma-delta T cell based CAR construct, nsCAR)

Target CD33/CD123

Status note Preclinical program suspended in development due to pipeline prioritization and market conditions; not formally discontinued.

INB-500

Preclinical · Active Modality: cell therapy (gamma-delta T cells from iPSCs)

Status note Preclinical iPSC gamma-delta T cell program suspended in development due to pipeline prioritization and market conditions; not formally discontinued.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Autologous genetically modified gamma-delta T cells
Lead indication	Glioblastoma
Lead phase	Phase 2
Active trials	1
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05664243	Phase 2	Active, not recruiting	Sponsor	INAB	—	Glioblastoma	—
NCT03533816	Phase 1	Recruiting	Collaborator	University of Kansas Medical Center	—	Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for In8bio Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Stonepine Capital	695,287	+31,875	0.75%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

INAB — IN8bio Inc. ☆

What they do

Balance sheet

Share structure

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

INAB — IN8bio Inc.